Ironwood Pharmaceuticals Inc (IRWD)

Return on equity (ROE)

		Dec 31, 2023	Sep 30, 2023	Jun 30, 2023	Mar 31, 2023	Dec 31, 2022	Sep 30, 2022	Jun 30, 2022	Mar 31, 2022	Dec 31, 2021	Sep 30, 2021	Jun 30, 2021	Mar 31, 2021	Dec 31, 2020	Sep 30, 2020	Jun 30, 2020	Mar 31, 2020	Dec 31, 2019	Sep 30, 2019	Jun 30, 2019	Mar 31, 2019
Net income (ttm)	US$ in thousands	-1,002,242	-952,288	-917,292	181,978	175,065	167,572	173,100	527,323	528,448	530,278	508,856	142,757	106,176	110,830	97,055	84,134	21,505	-41,846	-236,845	-298,508
Total stockholders’ equity	US$ in thousands	-346,295	-323,216	-345,704	706,852	652,378	591,063	532,883	517,783	605,911	579,941	511,756	110,192	62,640	5,904	-36,852	-71,557	-93,251	-153,047	-219,367	-237,179
ROE		—	—	—	25.74%	26.83%	28.35%	32.48%	101.84%	87.22%	91.44%	99.43%	129.55%	169.50%	1,877.20%	—	—	—	—	—	—

December 31, 2023 calculation

ROE = Net income (ttm) ÷ Total stockholders’ equity
= $-1,002,242K ÷ $-346,295K
= —

Based on the provided data, the return on equity (ROE) of Ironwood Pharmaceuticals Inc has fluctuated over the past eight quarters. In Q1 2022, the ROE was exceptionally high at 101.84%, indicating that the company generated substantial profits relative to its shareholders' equity. However, this figure experienced a significant decline in subsequent quarters.

Throughout Q2 2022 to Q3 2023, the ROE ranged from 26.83% to 32.48%, displaying a relatively stable performance during this period. This suggests that Ironwood Pharmaceuticals Inc was able to maintain a healthy level of profitability compared to the amount of shareholder equity invested in the company.

The absence of data for Q4 2023 prohibits a detailed analysis of the most recent quarter's ROE. However, investors and stakeholders should monitor future ROE figures to assess the company's ongoing ability to generate returns for its shareholders.